{"id":"W3091806433","doi":"10.1016/j.cgh.2020.10.003","title":"Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis","year":2020,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":61,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University","funders":"UCB Pharma; Janssen Pharmaceuticals; Ferring Research Institute; University of California, San Diego; Genentech; Agency for Healthcare Research and Quality; Tillotts Pharma; Toray Industries; Otsuka Pharmaceutical; National Institute of Diabetes and Digestive and Kidney Diseases; MedImmune; Kyowa Hakko Kirin; Eisai; Celltrion; Western University; Covis Pharma; Eli and Edythe Broad Foundation; Crohn's and Colitis Foundation; School of Public Health, University of California Berkeley; Novo Nordisk; Vertex Pharmaceuticals; Regeneron Pharmaceuticals; American College of Gastroenterology; Takeda Pharmaceutical Company; AbbVie; Teva Pharmaceutical Industries; Takeda Oncology; Luitpold Pharmaceuticals; Ironwood Pharmaceuticals, Incorporated; Takeda Pharmaceuticals North America; Allergan; Seres Therapeutics; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb; Shire; Novartis Pharmaceuticals Corporation; Biogen; Pfizer; ActoGeniX; Boehringer Ingelheim; Amgen; Gilead Sciences; Celgene; GlaxoSmithKline","keywords":"Vedolizumab; Medicine; Internal medicine; Ulcerative colitis; Infliximab; Adverse effect; Antagonist; Gastroenterology; Tumor necrosis factor alpha; Disease","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002304571,0.0004320759,0.001972043,0.0009325178,0.0002515391,0.00106065,0.0005544191,0.001056182,0.002871612],"category_scores_gemma":[0.003830503,0.0002662232,0.001539728,0.0005634124,0.001007417,0.001323654,0.0002668338,0.001685831,0.0005546329],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007793612,"about_ca_system_score_gemma":0.0004526752,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004507124,"about_ca_topic_score_gemma":0.0007032445,"domain_scores_codex":[0.9983897,0.0009641415,0.0001436082,0.0001407882,0.0001579247,0.0002037521],"domain_scores_gemma":[0.9977071,0.001215008,0.0003757013,0.0001882254,0.0001445717,0.0003692965],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8876212,0.003500585,0.004467547,0.0005028442,0.001640154,0.000168914,0.00008333253,0.0006689198,0.01401524,0.0003228998,0.0003718235,0.08663649],"study_design_scores_gemma":[0.2543557,0.6386442,0.08385398,0.0002701185,0.004413403,0.0007773046,0.0002915149,0.002012358,0.00958005,0.000816668,0.004906576,0.00007825666],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9785055,0.01781407,0.0002896524,0.0002554153,0.0002491928,0.00008395452,0.0003972722,0.00002302342,0.002381935],"genre_scores_gemma":[0.9964117,0.002134808,0.0001365017,0.0001532697,0.0003036811,0.00004627076,0.0003693888,0.000007263362,0.000437011],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002871612,"threshold_uncertainty_score":0.0121879,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03388614147308523,"score_gpt":0.3344459684819445,"score_spread":0.3005598270088593,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}